Skip to main content

Peer Review reports

From: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Original Submission
9 Mar 2022 Submitted Original manuscript
24 Apr 2022 Reviewed Reviewer Report - Muslim Syed
14 Dec 2022 Reviewed Reviewer Report - Zhaohua Zhu
30 Dec 2022 Author responded Author comments - Wei Bai
Resubmission - Version 2
30 Dec 2022 Submitted Manuscript version 2
1 Jan 2023 Reviewed Reviewer Report - Zhaohua Zhu
4 Jan 2023 Reviewed Reviewer Report - Muslim Syed
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
10 Jan 2023 Editorially accepted
15 Feb 2023 Article published 10.1186/s13063-023-07087-5

You can find further information about peer review here.

Back to article page

Trials

ISSN: 1745-6215